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ABSTRACT

Resistance Training Increases the Expression of AMPK, mTOR, and GLUT4 in Previously
Sedentary Subjects and Subjects with the Metabolic Syndrome

by
Andrew Steven Layne
Exercise has been considered a cornerstone of diabetes prevention and treatment for decades, but
the benefits of resistance training are less clear. Nineteen non-diabetic subjects (10 metabolic
syndrome, 9 sedentary controls) underwent 8 weeks of supervised resistance training. After
training, strength and V O2max increased by 10% in both groups. Percent body fat decreased in
subjects with the metabolic syndrome. Additionally, lean body mass increased in both groups
(p<0.05). Expression of glucose transporter protein-4 (GLUT4), the principle insulin-responsive
glucose transporter, increased significantly in both groups. 5-adenosine monophosphateactivated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) expression
increased in both groups, indicating increased protein synthesis and mitochondrial biogenesis.
Markers of insulin resistance measured by a euglycemic hyperinsulinemic clamp did not improve
in subjects with the metabolic syndrome but increased significantly in control subjects (13%).
Resistance training upregulates intracellular signaling pathways that may be beneficial for
ameliorating the metabolic syndrome.
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CHAPTER 1
INTRODUCTION
Problem Statement
The prevalence of the metabolic syndrome is increasing rapidly worldwide. Exercise
causes an array of physiological adaptatations that may ameliorate many aspects of the metabolic
syndrome. The purpose of this study was to identify the role of several molecular mediators that
are potentially responsible for the beneficial adaptations to 8 weeks of resistance training in
subjects with the metabolic syndrome.
Review of the Literature
The Metabolic Syndrome
Advancements in technology over the past century have greatly improved the quality of
life for humans across the globe. Consequently, many humans have become less physically
active and have relatively unimpeded access to excessively rich nutrition, particularly in
developed and developing countries (1-3). These and other lifestyle and behavioral changes have
led to a marked increase in the prevalence of obesity and other metabolic disorders (4). Over the
past 20 years, the number of people diagnosed with metabolic abnormalities has increased
dramatically (5;6). Several studies indicate that over half of all U.S. adults are overweight (BMI
> 25kg/m2) (1;7;8), and as many as 1 in 4 U.S. adults meet the criteria for having metabolic
syndrome (9;10). The average life expectancy in the U.S. may soon decrease for the first time
due to obesity-related illness (11). Individuals with the metabolic syndrome are at an increased
risk for developing cardiovascular disease (CVD), type 2 diabetes (9), and for mortality from
CVD (10). The prevalence of the metabolic syndrome is continuing to rise (12), highlighting the
need for the development of effective prevention and treatment strategies.
8

The metabolic syndrome has existed conceptually since at least the 1920s (5;13), when a
Swedish physician named Kylin described the association of hypertension and hyperglycemia
(13). Later, obesity (particularly visceral obesity) was observed to be associated with type 2
diabetes and CVD (13;14). The term “metabolic syndrome,” the most commonly used term for
the syndrome, was coined in the 1970s by German researchers (15). In 1988, Reaven described
what he termed Syndrome X: insulin resistance, hyperglycemia, hypertension, and low HDLcholesterol (16). Because these risk factors tend to occur in the same individual, Reaven
suggested that the body’s attempt to compensate for these risk factors, particularly insulin
resistance, leads to the development of coronary artery disease (16). Around the same time,
Ferrannini et al. coined the term “insulin resistance syndrome” and concluded that insulin
resistance is the underlying cause of risk factors for coronary artery disease (17). Based on these
observations, it became apparent that a criterion for diagnosing patients at risk of developing
type 2 diabetes and CVD was essential for detection and treatment of the metabolic syndrome.
Definitions of the Metabolic Syndrome
Since the late 1990s, several groups have established guidelines for clinical diagnosis of
the metabolic syndrome. According to guidelines published by the World Health Organization in
1999, a patient is considered to have the metabolic syndrome if he or she has diabetes, impaired
glucose tolerance, impaired fasting glucose, or insulin resistance as well as 2 or more of the
following: high resting blood pressure (140/90 mmHg); hyperlipidemia (triglyceride
concentration ≥150 mg/dL) and/or HDL cholesterol <35 mg/dL in men and <39 mg/dL in
women; waist-to-hip ratio of >0.90 in men or >0.85 in women and/or BMI >30kg/m2;
microalbuminuria (urinary albumin excretion rate ≥20 µg/min or albumin:creatinine ratio ≥20
mg/g (18;19). It was soon realized that the WHO definition was inadequate for the clinical
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setting because of the need for a euglycemic insulin clamp procedure to identify insulin
resistance (20).
Since the original guidelines published by the WHO, other groups have published various
definitions of the metabolic syndrome. The European Group for the Study of Insulin Resistance
released an alternative definition in 1999. In 2002, the National Cholesterol Education Program’s
Adult Treatment Panel III report (ATP III) released slightly different guidelines. A diagnosis
under ATP III guidelines requires abdominal obesity (defined as a waist circumference >102 cm
in men and >88 cm in women); triglycerides ≥150 mg/dL; HDL cholesterol <40mg/dL in men
and <50mg/dL in women; resting blood pressure ≥130/85 mmHg; and fasting glucose ≥110
mg/dL (9;21). The ATP III definition does not require a euglycemic clamp for diagnosis, making
it more applicable for the clinical setting than the WHO definition.
Following the release of the ATP III definition of the metabolic syndrome, the American
Association of Clinical Endocrinologists (AACE) developed a modified version of the ATP III
definition; however, it has received criticism due to its exclusion of obesity as a key factor in the
metabolic syndrome (3;20).
The growing number of definitions of the metabolic syndrome along with the
discrepancies in diagnosis criteria highlighted the need for a unifying definition of the syndrome
(10). In 2005, the International Diabetes Federation (IDF) proposed a new set of guidelines with
the hope of accomplishing such a goal (20). The IDF guidelines focused on central adiposity as a
requirement for diagnosis of the metabolic syndrome. In addition to central adiposity, diagnosis
of the metabolic syndrome under the IDF definition requires 2 or more of the following:
triglycerides ≥150 mg/dL; reduced HDL cholesterol <40mg/dL in males and <50mg/dL in
females or specific treatment for this lipid abnormality; raised resting blood pressure ≥130/85

10

mmHg; family history of diabetes (first-degree relative); and pre-existing CVD (6;22).
Additionally, the IDF published ethnic-specific cut off values for waist circumference, a measure
of central obesity (6).
Prevalence of the Metabolic Syndrome
Several studies and meta-analyses have been conducted to determine the actual
prevalence of the metabolic syndrome using differing definitions of the syndrome (3). A 2006
study compared the prevalence of the metabolic syndrome in Japanese men and women when
using the ATP III and IDF definitions. Of the 2228 people in the study, 37.3% of men and 4.4%
of women were diagnosed with metabolic syndrome according to the IDF definition, and 26.9%
of men and 14.7% of women were diagnosed using the ATP III definition (23). A low number of
women with a waist circumference greater than 90 cm could account for much of the
discrepancy in the rate of diagnosis between men and women in this study. A similar study was
conducted with Asian Indians in Chennai, India. 2350 individuals aged ≥20 years were screened
for metabolic syndrome using the WHO, ATP III, and IDF definitions. The percentage of men
diagnosed with metabolic syndrome was similar to the rates found Japanese males.
Approximately 23.3%, 28.3%, and 25.8% of males were identified as having metabolic
syndrome according to the WHO, ATP III, and IDF definitions in Asian Indians, while 19.7%,
19.4%, and 28.2% of females were diagnosed with metabolic syndrome using the same
definitions. Interestingly, only 224 of the subjects were diagnosed by all three criteria (24).
Another study in Jaipur, India found that out of 1091 participants, 9.8% of men and 20.4% of
women were diagnosed with metabolic syndrome according to the ATP III definition (25)
Additional studies have been conducted in countries throughout the world. According to
the ATP III definition of the metabolic syndrome, the prevalence in European countries ranges
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from 10% in French men and 7% in French women (26) to 26.2% in Scottish men (27).
According to the WHO definition, the prevalence of the metabolic syndrome in Europe ranges
from 44% in British men and 33.9% in British women to 12.2 % in Italian men and 5.1% in
Italian women (28). The prevalence in the Mexican population was found to be 26.6% and
13.6% according to the ATP III definition and the WHO definition, respectively (29). A metaanalysis of studies using the ATP III and WHO definitions of the metabolic syndrome indicated
that the prevalence of the metabolic syndrome ranges from 8.8% to 92.3% in the United States
and Europe; however, the studies that reported the highest rates of metabolic syndrome used
participants who had already been diagnosed with type 2 diabetes. The meta-analysis indicated
that the metabolic syndrome is an important risk factor for CVD, and that the association of the
metabolic syndrome with risk of cardiovascular disease was higher in studies that used the WHO
definition of the metabolic syndrome compared to the ATP III definition (30).
Several studies have been conducted in the United States in an attempt to determine the
prevalence of the metabolic syndrome across different age and ethnicity groups. A study of 439
U.S. children between 4 and 20 years old used an age-adjusted version of the ATP III definition
of the metabolic syndrome and found that the prevalence of the metabolic syndrome was 38.7%
in moderately obese participants and 49.7% in severely obese subjects. In this particular study,
no overweight or normal participants met the criteria for metabolic syndrome (31). The study
found that the percentage of subjects with glucose intolerance increased with the severity of the
obesity regardless of ethnicity, and biomarkers of increased risk of cardiovascular complications
(decreased adiponectin, increased C-reactive protein) were already present in these children.
In U.S. adults, the prevalence of the metabolic syndrome varies depending on the criteria
used for diagnosis and the age and ethnicity of the population measured (3). Meigs and others
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(32) conducted a study of the prevalence of the metabolic syndrome according to the WHO and
ATP III definitions in non-Hispanic white and Hispanic subjects. The study found the
prevalence of the metabolic syndrome among white U.S. adults to be 26.7% by ATP III criteria
and 27.3% by WHO criteria. The prevalence among Hispanic subjects was 41.4% (ATP III) and
41.1% (WHO). A 2005 study by Ford sought to compare the prevalence of the metabolic
syndrome using the IDF and ATP III definitions. The study concluded that the prevalence of the
metabolic syndrome among all U.S. adults is 40.5% according to the IDF definition and 34.5%
according to the ATP III definition. Ford (6) also noted increased prevalence of the metabolic
syndrome across all ethnic groups as age increased. Similarly, Alexander et al. (15) found the
prevalence of the metabolic syndrome among U.S. adults ≥50 years old to be 43.5% according to
the ATP III definition. Earlier studies by Ford (10;33) indicate the unadjusted and age-adjusted
prevalence of the metabolic in the United States is 21.8% and 23.7, respectively. Park and others
(34) found similar prevalence rates (22.8% in men and 22.6% in women).
Studies indicate a high prevalence of the metabolic syndrome in the U.S. and worldwide,
and the prevalence is expected to rise in the future. The presence of the metabolic syndrome in
children and the increased prevalence among older adults indicates that the metabolic syndrome
could be a lifelong struggle for a relatively large portion of the population; therefore, practical
and cost-effective measures for ameliorating the risk of developing the metabolic syndrome are
essential.
Clinical Outcomes of the Metabolic Syndrome
CVD and type 2 diabetes are recognized as the main clinical outcomes of untreated
metabolic syndrome (9;13;33;35;36). Isomaa et al. (37) found a threefold increase in the risk for
coronary heart disease and stroke in subjects with metabolic syndrome versus those without, and
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cardiovascular mortality rate was 12% in subjects with metabolic syndrome and only 2.2% in
those without. A review by Ford (38) indicates that the population-attributable fraction for the
metabolic syndrome is 12-17% for CVD and 30-52% for diabetes. Ford also notes a relative risk
of 1.65 for CVD and 2.99 for diabetes in studies using the ATP III definition of the metabolic
syndrome. A meta-analysis by Gami et al. (39) concluded that subjects with the metabolic
syndrome had a relative risk of 1.78 of cardiovascular events and death in studies between 1971
and 1997. A more recent meta-analysis found that individuals with the metabolic syndrome have
relative risk factor of 1.17 for mortality from CVD, as well as a relative risk of 1.53 for incidence
of CVD, 1.52 for coronary heart disease, and 1.76 for stroke (30). These and numerous other
studies point to the metabolic syndrome as an important risk factor for CVD related events and
type 2 diabetes. The complications from CVD and type 2 diabetes cost individuals thousands of
dollars each year (40), and the enormous human and monetary toll on society explains much of
the recent research interest in the underlying causes and risk factors involved in the development
of these diseases.
Molecular Basis of the Metabolic Syndrome

Blood Glucose
Glucose is the primary fuel source most tissues in the body, including skeletal muscle and
the brain (41). Many cells rely on a small amount of glucose that is constantly circulating in the
blood. Blood glucose is maintained at a fasting level of about 80 to 90mg/100ml of blood. A
sharp decrease in circulating blood glucose (20 to 50 mg/100ml of blood) can lead to
neuroglycopenia, seizure, and even death; however, chronically elevated blood glucose levels
can lead to ß-cell dysfunction and other complications associated with diabetes (42). Due to the
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importance of blood glucose, an extensive physiological monitoring and control system has been
developed for maintaining blood glucose at a normal level.
In 1921, Banting and Best (43) discovered pancreatic secretions that led to temporary
increases in blood glucose, and insulin was soon isolated from the secretions. In 1923, Murlin
and others proposed the possibility of a second pancreatic hormone that they termed glucagon
(44). Insulin and glucagon are secreted directly into the blood via islets of Langerhans. The islets
contain alpha, beta, and delta cells of which 60% are beta cells. Beta cells produce insulin while
alpha cells, which comprise about 25% of the cells in the islets, produce glucagon (45).
Role of Glucagon and Insulin in Blood Glucose Regulation
The development of an immunoassay for glucagon by Unger and colleagues (46) allowed
researchers to determine if glucagon can be indentified in circulation and how its secretion
influences blood glucose (47). Glucagon exerts a hyperglycemic effect when released into the
bloodstream. As little as 1µg/kg of glucagon can raise blood glucose levels by 25% in 20
minutes (45). Glucagon primarily increases blood glucose levels by initiating glycogenolysis in
the liver, a process by which glycogen is converted to glucose-1-phosphate (48). Once
dephosphorylated, glucose is released from liver cells into the bloodstream, thus raising blood
glucose levels. Glucagon is also responsible for gluconeogenesis in the liver, a process by which
glucose is created from amino acids (49). Gluconeogenesis can provide about 180g of glucose
during a 24-hour fast (50).
Insulin primarily affects the metabolic machinery within skeletal muscle cells. Insulin
binds to receptors on the outside of the cell membrane that causes phosphorylation of
intracelluclar enzymes. Phosphorylation of these enzymes causes increases in growth and gene
expression as well as increases in fat, protein, and glucose synthesis. Insulin also causes the cell
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membrane to become more permeable to glucose, particularly in skeletal and adipose cells (45).
The increased permeability of the cell membrane to glucose is due to translocation of vesicles
contained within the cell which release glucose transport proteins at the cell membrane. These
glucose transport proteins bind with the cell membrane and facilitate glucose uptake into the cell
(51). During periods of time when insulin secretion is high such as after a meal, muscle cells use
glucose as the preferred fuel source over fatty acids. When glucose is not needed for energy in
muscle cell, it can be stored as glycogen for later use (45).
Insulin exerts slightly different effects on other tissues in the body. In the liver, insulin
acts primarily to increase storage of glucose. Insulin accomplishes this by increasing hepatic cell
permeability to glucose and by inactivating liver phosphorylase. Insulin also activates glycogen
synthase, an enzyme involved in glycogen formation (52). The liver generally stores about 100
grams of glucose which can be released between meals to maintain blood glucose (53).
Insulin also affects fat metabolism. The continuous availability of food is a recent
development for humans, and humans have yet to adapt; therefore, the body attempts to store
nutrients when they are plenty. As previously noted, insulin release can be associated with the
increased use of glucose as a fuel source, which effectively spares fat. Additionally, insulin
increases fatty acid synthesis and storage and inhibits phosphorylation of hormone-sensitive
lipase (HSL), a hormone responsible for fatty acid mobilization (54). Insulin also increases
adipose cell membrane permeability to glucose, which is used to form α-glycerol phosphate, a
substance that provides the glycerol backbone of triglycerides (55). In the liver, glucose that is
not stored as glycogen can be split into pyruvate through the glycolytic pathway. Pyruvate is then
converted into acetyl-coenzyme A (acetyl CoA) (56), a necessary substrate for fatty acid
synthesis. When glucose is being used for energy, citrate and isocitrate ions activate acetyl-CoA
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carboxylase (ACC), an enzyme required for the reductive synthesis of fatty acids from acetylCoA and malonyl-CoA (57). Triglycerides formed through these pathways are then released into
the blood stream in lipoproteins for uptake and storage in adipose tissue.
Physiological Regulation of Glucagon and Insulin Release
Several feedback mechanisms are in place to influence secretion and clearance of insulin
and glucagon. The main stimulus that initiates both insulin and glucagon secretion is changes in
the blood glucose level. As blood glucose levels fall from a normal level, glucagon is secreted to
correct the problem. As described earlier, glucagon causes the liver to increase its output of
glucose that raises blood glucose levels. Blood glucose is also a potent stimulator of insulin
release; however, its effects on insulin secretion are the opposite of those for glucagon. As blood
glucose levels rise above 100mg/100ml of blood, plasma insulin levels rise quickly. Plasma
insulin levels tend to “overshoot” initially, but insulin secretion is not maintained and plasma
levels decrease. After a short time, plasma insulin levels begin to rise again and reach a plateau
or steady state (58;59). As blood glucose levels return to normal, insulin secretion is rapidly
decreased.
While blood glucose is a potent stimulator of insulin release, other stimuli can cause
insulin secretion. Gastrointestinal hormones such as gastrin and secretin can initiate an
anticipatory increase in insulin secretion in response to feeding (60). Parasympathetic activation
of the pancreas can also cause insulin secretion and may contribute to postprandial insulin
secretory response (61).
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Glucose Uptake and Use in Skeletal Muscle
Skeletal muscle makes up a large percentage of an individual’s body mass, and is the
primary site for insulin-stimulated glucose uptake and use (62). As early as 1926, Best
demonstrated that insulin stimulates glucose uptake by skeletal muscle (63). A subsequent series
of studies by Gemmill demonstrated that insulin promotes glucose uptake in isolated rat
diaphragm muscle (64;65). In 1944, Gammeltoft noted that fructose and glucose uptake occurs
through separate mechanisms in perfused cat hind limbs (66). However, it was not until 1949
that Levine proposed the existence of a facilitated transport system for transporting sugars across
the membrane of skeletal muscle cells (67). Decades later, work in adipocytes elucidated the
possibility of glucose transport protein (GLUT) translocation from an intracellular pool to the
plasma membrane in the presence of insulin (68). Subsequent work led to the characterization
and cloning of glucose tranporter-4 (GLUT4) (69;70). The development of GLUT4 knockout
mice led to the realization that the absence of GLUT4 does not necessarily preclude the
development of diabetes, suggesting the presence of other GLUTs involved in glucose transport
(71-73)
Today, as many as 14 members of the GLUT hexose transport family have been
identified (74;75). Due to differences in tissue expression, structure, and function, the GLUT
family has been subdivided into three categories (74). Of these classes, class one GLUTs,
including GLUT1 through GLUT4 are the most extensively researched to date. GLUT4 is the
predominant transport protein in skeletal muscle cells; however, the mRNA for at least seven
other GLUT isoforms are present in skeletal muscle (75). Of these GLUTs, GLUT4, GLUT5,
and GLUT12 account for the vast majority of the GLUT isoform mRNA found in skeletal
muscle, and along with GLUT1, contribute most of the facilitated transport of hexoses through
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the plasma membrane. Furthermore, Stuart et al. (75) demonstrated that the fructose transporter
GLUT5 was predominantly expressed in type II muscle fiber, while GLUT12 was predominantly
expressed in type I muscle fibers. A subsequent study in humans demonstrated that GLUT12
accounts for as much as 12% of insulin-translocatable GLUTs and works together with GLUT4
to facilitate glucose uptake into muscle cells in response to insulin (76).
While it appears there is some redundancy to the GLUT system, GLUT4 accounts for the
majority of facilitated glucose transport through the sarcolemma in response to insulin and
exercise. Insulin stimulation can cause a 2- to 3- fold increase in GLUT4 translocation from
intracellular storage vesicles to the plasma membrane (77); however, the mechanisms behind
GLUT4 translocation have only recently been elucidated. Studies indicate that GLUT4 has
unique sequences in its N- and C- termini which contribute to its recycling and transport
characteristics (78). Piper et al (79) showed that the N-terminus contains a phenylalanine
targeting motif that when deleted or replaced with alanine at position 5 resulted in the
accumulation of GLUT4 in the plasma membrane. However, other groups have suggested that
the C- terminus is the most important targeting motif of GLUT4. In particular, the dileucine
motif in the C- terminus has been suggested to be important in the intracellular trafficking of
GLUT4 (80;81).
Insulin and exercise mediate endocytosis and exocytosis of GLUT4 through complex
signaling pathways that are not yet clearly understood; however, evidence suggests that insulindependent and exercise-induced glucose uptake occur through separate mechanisms and rely on
different intracellular GLUT4 pools (82). The plasma membrane of insulin-sensitive tissues
contain transmembrane tyrosine kinase insulin receptors (IR) which target IRS proteins when
bound with insulin (83). In particular, conformational change of the IR primarily phosphorylates
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IRS-1 and IRS-2 in skeletal muscle cells that attract phosphatidylinositol PI 3-kinase (PI3-K) to
their location (84). The signal is then transmitted through PDK1 and mammalian target of
rapamycin (mTOR) to other downstream targets, including two serine/threonine protein kinases,
Akt/protein kinase B (PKB) and atypical PKC (77). Activation of the Akt isoform Akt2 appears
to control GLUT4 trafficking in skeletal muscle cells (85), although the mechanisms are unclear.
Other substrates including platelet-derived growth factor (PDGF) and 5’ AMP-activated protein
kinase (AMPK) increase GLUT4 translocation to the plasma membrane. Currently, research is
being conducted to elucidate downstream cellular machinery responsible for GLUT4
translocation, including Rab GTPase Activating Protein (AS160) (86).
Exercise does not appear to cause phosphorylation of IRS-1, suggesting that exercise and
insulin signaling occur through separate pathways (87). Additionally, PI3-K inhibition by
wortmannin eliminates insulin-stimulated glucose uptake but not exercise-stimulated glucose
transport in contracting skeletal muscle (88). Exercise-induced glucose uptake occurs through at
least 2 possible pathways. Exercise causes a decrease in the ATP:AMP ratio, which is a powerful
stimulator of AMPK activity (89). AMPK is a heterotrimer with two catalytic α-subunits and two
regulatory subunits, ß and γ. Of the two α-subunits, α2 has the highest expression in skeletal
muscle (90) and has been suggested as the primary isoform responsible for metabolic adaptations
in human skeletal muscle (91). Phosphorylation at threonine residue 172 (Thr172) of AMPK by
the upstream serine/threonine protein kinase 11 (LKB1) stimulates AS160 and atypical PKC
which leads to GLUT4 translocation (92). The interaction of AMPK and AS160 in response to
exercise may explain the additive effect of the insulin and exercise stimulated GLUT4
translocation signaling pathways (93;94). Interestingly, impaired AS160 phosphorylation has
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been observed in individuals with type II diabetes; however, it is unclear if this defect
significantly contributes to insulin resistance (95).
Muscle contraction also causes the release of calcium from the sarcoplasmic reticulum,
which increases intracellular calcium concentration. Caffeine has been used to stimulate calcium
release independent of muscle contraction to determine the effects of calcium concentration on
glucose uptake (96). While the mechanisms are still unknown, conventional protein kinase C
(PKC) and calcium/calmodulin-dependent protein kinase (CaMK) are potential intracellular
proteins responsible for contraction-stimulated glucose uptake (93). Inhibition of LKB1 results in
a decrease in contraction-stimulated glucose uptake; however, inhibition of AMPK
phosphorylation has little to no effect on contraction-stimulated glucose uptake, suggesting an
AMPK-independent signaling pathway (97). CaMK-Kinases (CaMKK) have recently been
identified as upstream regulators of AMPK activity in skeletal muscle cells, and studies have
demonstrated that CaMKKα may be implicated in glucose uptake signaling (97-99). More
reasearch is needed to elucidate the signaling pathway responsible for the increase in glucose
uptake following muscle contraction.
The importance of GLUT4 in regulating blood glucose in response to insulin and exercise
has made GLUT4 a major target for the treatment and prevention of the metabolic syndrome and
diabetes. It has been demonstrated that a single bout of exercise is enough to increase GLUT4
gene expression in skeletal muscle (100). Several short- and long-term training studies have also
demonstrated increases in GLUT4 expression in response to exercise (101-105). More recent
human studies have shown increases in skeletal muscle (106;107) and whole body (108;109)
glucose uptake, possibly due to exercise-induced increases in GLUT4 expression. Furthermore,
epidemiological studies indicate that physical inactivity increases the risk of developing type 2
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diabetes in humans (110), which underscores the important role of GLUT4 expression and
exercise in the prevention of insulin resistance.
Insulin Resistance and the Metabolic Syndrome
In 1939, Himsworth observed that the decreased ability of tissues to take up glucose is
the major underlying defect of diabetes mellitus (111). Twenty years later Yalow and Berson
(112) developed an immunoassay of endogenous plasma insulin that was sufficiently specific
and sensitive to measure plasma insulin levels. Using this immunoassay, Yalow and Berson
demonstrated that subjects with type II diabetes had higher fasting plasma insulin levels than
non-diabetic subjects, and diabetic subjects had a delayed insulin response when given an oral
glucose load. These findings were later confirmed by other studies (113-115). Interestingly, these
studies indicate that normal and obese non-diabetic subjects reach a higher plasma insulin
concentration in response to a glucose load when compared to diabetic subjects.
Longitudinal studies indicate that the development of insulin resistance occurs prior to
the development of hyperglycemia (116-119). Accordingly, recent research has begun to link
obesity to insulin resistance, as opposed to the traditional “glucocentric” view of the metabolic
syndrome (5). As discussed previously, most widely accepted definitions of the metabolic
syndrome include some measure of abdominal obesity in the diagnostic criteria. Indeed, high
plasma triglycerides and reduced HDL cholesterol are typically seen in individuals with
abdominal obesity (120). Moreover, increased plasma free fatty acid (FFA) concentration is
elevated in obese subjects (121), possibly due to increased fat mass (122). In 1963, Randle and
coworkers (123) found that FFA interfere with the oxidation of glucose in rat heart and
diaphragm muscle in vitro. This finding remained controversial until recent studies demonstrated
similar findings in human skeletal muscle. In 1996, Roden et al. (124) observed a decrease in
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carbohydrate oxidation following lipid infusion under euglycemic insulin clamp conditions in
humans. Roden concluded that elevated plasma FFA content “causes insulin resistance by
inhibition of glucose transport and/or phosphorylation with a subsequent reduction in rates of
glucose oxidation and muscle glycogen synthesis.” A subsequent study by Santomauro et al.
(125) showed that treatment with an antilipolytic drug, Acipimox, reduced fasting plasma FFA
and insulin concentrations in obese subjects. Furthermore, euglycemic-hyperinsulinemic clamps
and glucose tolerance tests revealed improved glucose tolerance after plasma FFA reduction in
obese non-diabetic patients and obese patients with type 2 diabetes.
Although link exists between obesity and insulin resistance, the mechanisms behind this
relationship are less clear. Recent investigations attempting to explain this relationship have
focused on the endocrine functions of adipose tissue. Tumor necrosis factor-alpha (TNF-α) is a
cytokine produced primarily in macrophages which has been shown to be elevated in obese
rodent and human models. In rodents, over-expression of TNF-α has been shown to induce
peripheral insulin resistance, which is restored with neutralization of TNF-α (126). In humans, it
has been demonstrated that obese subjects express significantly more TNF-α mRNA in fat tissue
than in lean controls, and a strong positive correlation exists between TNF-α mRNA expression
and hyperinsulinemia (127-129). Furthermore, TNF-α mRNA expression and insulin
insensitivity decreased with a corresponding reduction in body mass (127). Other studies failed
to find a relationship between TNF-α secretion and insulin sensitivity in vivo in humans
(130;131), possibly due to differences in sample collection and analysis used in these studies.
Nonetheless, Feinstein and others examined the effect of TNF-α on rat Fao hepatoma cells to
determine the mechanism behind TNF-α induced insulin resistance. As discussed previously,
insulin exerts its effects at the cellular level by binding to insulin receptors on the cell surface.

23

The binding of insulin to the α-subunit of the IR activates the tyrosine kinase in the ß-subunit,
which is necessary for insulin action in the cell. Feinstein and coworkers (132) demonstrated that
TNF-α exposure inhibits tyrosine phosphorylation of the IR ß-subunit and IRS-1 in Fao cells,
which inhibits insulin receptor signaling. This finding suggests a possible mechanism for
obesity-induced insulin resistance.
Adipose tissue also secretes interleukin-6 (IL-6), another cytokine associated with
inflammation. Similar to TNF-α, high plasma concentrations of IL-6 correspond to increased
obesity and insulin resistance (128;133;134). Kern et al. (128) demonstrated that IL-6 may affect
insulin sensitivity in mouse hepatocytes and human HepG2 cells via similar mechanisms to
TNF-α. Specifically, IL-6 may inhibit IR activity due to decreased tyrosine phosphorylation of
IRS-1, which inhibits insulin-dependent activation of Akt. However, a study in IL-6-deficient
(IL-6-/-) mice indicates that hypothalamic IL-6 may exert anti-obesity effects (135). IL-6-/- mice
developed type 2 diabetes, which was partially ameliorated by IL-6 treatment. Furthermore,
substrate metabolism was impaired in IL-6-/- mice. Similarly, studies in human skeletal muscle
indicate that IL-6 exposure improves glucose metabolism but has no effect on insulin-dependent
glucose uptake (136). It has been demonstrated that contracting skeletal muscle produces IL-6,
which leads to an increase in plasma IL-6 levels (137). Recent evidence suggests that the effects
of IL-6 vary depending on the target tissue. Chronic elevation of circulating IL-6 levels are an
indicator of insulin resistance, while the acute presence of IL-6 may be beneficial for certain
tissues such as skeletal muscle (138).
Other adipocyte secretions include plasminogen activator inhibitor 1 (PAI-1) and
apidonectin. PAI-1 has recently been linked to the development of thrombosis, fibrosis, and
insulin resistance (139). Using PAI-1 deficient mice Ma and colleagues demonstrated that PAI-1

24

deficiency protects against diet-induced obesity and insulin resistance, suggesting that PAI-1
may be important in the development of obesity. Others have hypothesized that PAI-1
contributes to a “hypercoagulable” state, which may result in increased platelet formation and
associated cardiovascular risks (140). Adiponectin is a protein secreted by adipocytes.
Circulating levels of adiponectin are inversely related to obesity and insulin resistance, while upregulation of adiponectin protects against obesity-induced insulin resistance (141). Adiponectin
also acts as an insulin-sensitizing agent, possibly through phosphorylation and activation of the
AMPK signaling pathway (142).
While recent work has elucidated many potential mechanisms by which insulin resistance
develops, the underlying cellular processes are poorly understood. The concept of obesity as a
chronic state of inflammation is supported by evidence that adipocytes release inflammatory
mediators, and subsequent work has shown that obese individuals generally express abnormal
levels of these inflammatory markers. As discussed earlier, CVD is the primary clinical outcome
of the metabolic syndrome. Obesity has been linked to proven mechanisms contributing to the
development of CVD and an increased risk of cardiovascular events (140) including
atherosclerosis, hypercholesterolemia, increased blood viscosity, and platelet dysfunction (143).
Interestingly, weight loss has been shown to reduce inflammatory markers and improve insulin
resistance in humans (144-146), which suggests that weight reduction by dietary alterations or
increased physical activity may be an effective means of ameliorating the effects of the
metabolic syndrome.
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Exercise and the Metabolic Syndrome
The health benefits of regular physical exercise have been widely reported. Regular
physical exercise is beneficial in alleviating the independent risk factors for the metabolic
syndrome, including reduced systolic and diastolic blood pressure (147), improved body
composition (148), modestly increased HDL cholesterol (149-151), and slight lowering of serum
triglycerides (possibly due to weight loss) (151;152). Moreover, exercise can improve insulin
sensitivity acutely and chronically (153). In a study by Katzmarzyk et al. (154), 30.5% of the
subjects originally diagnosed with the metabolic syndrome no longer met the ATP III criteria for
the metabolic syndrome after 20 weeks of endurance training, illustrating the effectiveness of
exercise as a means to treat and prevent the metabolic syndrome. In fact, cardiovascular fitness
level has been shown to be associated with the incidence of the metabolic syndrome (155-157).
Exercise has been recognized as an essential component in the management of the
metabolic syndrome and diabetes for decades (110). Until recently, much of the available
research focused on endurance training as a means to alleviate the metabolic syndrome; however,
individuals at risk for developing the metabolic syndrome and type 2 diabetes tend to have a
greater preponderance of type II muscle fibers (158) which may make endurance training poorly
tolerated. A growing body of literature indicates that resistance training is a safe and effective
alternative for reducing the risk of the metabolic syndrome (159-163).
Endurance and resistance training have been shown to improve glycemic control
(159;164;165) and insulin resistance (165-167). However, the physiological adaptations that
contribute to these improvements differ depending upon the type of exercise performed. For
example, endurance training causes an increase in mitochondrial biogenesis, oxidative enzymes,
and fatty acid oxidation in type I muscle fibers (168-171), while resistance training does not
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(172-174). Additionally, endurance training increases capillary density (168), while capillary
changes in response to resistance training are less clear (173;175); however, both forms of
training seem to increase blood flow to skeletal muscle (173;176). Recent work has begun to
elucidate the molecular basis for the diverse adaptations to different training modalities.
Muscle Fiber Composition
Skeletal muscle shows remarkable plasticity in response to training. Even acute exercise
can cause an increase in protein synthesis (177) and mitochondrial oxidative enzymes (178;179);
however, endurance and resistance exercise seem to exert a number of their effects on type I and
type II muscle fibers, respectively (180). Muscle fiber type is largely determined by the motor
neuron that innervates it, as demonstrated by cross-innervation studies in cat hindlimb muscles
(181). The α-motor neuron and all of the muscle fibers it innervates make up a motor unit (182).
Burke and coworkers (183) identified three types of motor units based on certain contractile
properties. Slow twitch (type S) motor units develop relatively low force, speed, and power and
have the longest time to peak force (182); however, they are fatigue resistant, have high
oxidative and mitochondrial enzyme content and have extensive capillarization. Another motor
unit type, fast-twich fatigue sensitive (type FF), produce the greatest speed and force of
contraction, as well as the highest peak force. Unlike type S motor units, type FF have low
mitochondrial enzyme content and capillarization, which contributes to their high susceptibility
to fatigue; however, type FF have high glycogen content. A third, intermediate motor unit termed
fast-twitch fatigue resistant (type FR) expresses properties of type S and type FF motor units.
Type FR produce moderate force and speed of contraction, and contain moderate levels of
glycogen and mitochondrial enzymes, which makes them somewhat fatigue resistant (184).
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The muscle fibers that make up a motor unit have traditionally been identified based on
the myosin ATPase activity of the fibers. Myosin is a contractile protein that - along with actin makes up the majority of myofibril protein content. Myosin consists of two subunits – heavy and
light meromyosin (HMM and LMM, respectively). HMM-S1 is a globular fragment of HMM that
contains two myosin heads. Within HMM-S1 are myosin heavy chains (MHC), the primary
determinants of the ATPase activity and the speed of contraction of a muscle fiber (182;185).
Myosin light chains (MLC) are present in the neck region of the myosin molecule, and the
isoforms of MHC and MLC are the primary determinants of muscle fiber type classification
(182). Peter et al. (186) identified three types of muscle fibers in rabbit and guinea pig hindlimb
muscles using myosin ATPase and metabolic enzyme activity. Based on metabolic activity, the
authors proposed a new classification system consisting of fast-twitch glycolytic (FG), fasttwitch oxidative-glycolytic (FOG), and slow-twitch oxidative (SO) motor units. Another
classification system is based on the observation that fast and slow myosin ATPase enzymes
have different alkaline and acidic stability (187). Brooke and Kaiser (188) found that type IIx
fibers (fast twitch) are intensely stained for ATPase activity after preincubation at pH 10.4, while
preincubation at pH 4.6 results in strong staining of type I (slow-twitch) fibers. Additionally, the
intermediate type IIa fibers are moderately stained at pH 4.6. More recently, Behan and
colleagues (189) demonstrated that MHC type 1 and MHC type 2 can be labeled using
differently tagged monoclonal antibodies. Type IIx muscle fibers contain little or no MHC type
1, while type IIa fibers contain a mixture of MHC type 1 and 2, which allows for differentiation
of type IIa and IIx muscle fibers.
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Bioenergetics of Exercise
Normal human skeletal muscle contains a mixture of type I, IIa, and IIx muscle fibers.
The metabolic and enzymatic properties of these fibers make them suited for different types of
activity. As discussed briefly, type II muscle fibers fatigue quickly but have rich glycogen stores.
Resistance exercise is generally short term, high intensity work. Energy for resistance exercise is
primarily supplied through the phosphagen and glycolytic systems. At the onset of exercise,
adenosine triphosphate (ATP) is hydrolyzed during muscle contraction in a reaction catalyzed by
myosin ATPase. Hydrolysis of ATP produces ADP and inorganic phosphate (Pi). In order to
rapidly produce ATP, creatine kinase catalyzes a reaction in which the phosphate group of
phosphocreatine (PCr) is donated to ADP, which results in ATP formation (182). ATP can also
be rapidly produced via the myokinase reaction, whereby two ADP are used to form ATP and
AMP. Type II muscle fibers generally contain higher concentrations of phopshagens than type I
muscle fibers (190); however, phosphagens can only supply energy for about 10-15 seconds of
high intensity work. Fast glycolysis is the primary energy system used during high and
moderately high intensity exercise lasting between approximately 30 seconds and 2 minutes. Fast
glycolysis involves the breakdown of carbohydrates, particularly blood glucose or glycogen, into
pyruvate. Fast glycolysis nets 2 molecules of ATP for each molecule of glucose consumed. Each
of the reactions involved in ATP production via fast glycolysis occurs without the presence of
molecular oxygen. In the continued absence of oxygen, pyruvate formed through fast glycolysis
is converted to lactate (50), which can act as an energy substrate during long-term exercise
(182;191). Slow glycolysis occurs in the presence of oxygen, when pyruvate produced through
fast glycolysis enters the matrix of the mitochondria and is converted to acetyl CoA. Formation
of citrate from oxaloacetate and the acetyl group of acetyl CoA marks the beginning of the Krebs
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cycle. The Krebs cycle produces 2 molecules of GTP that can be converted into ATP. More
importantly, however, the Krebs cycle produces 6 molecules of nicotinamide adenine
dinucleotide (NADH) and 2 molecules of FADH2. These molecules are used in the inner
membrane of the mitochondria to produce ATP via oxidative phosphorylation (45;50). Overall,
anaerobic metabolism can produce 2 molecules of ATP from one molecule of glucose, while
aerobic mechanisms can produce 38 molecules of ATP from one molecule of glucose. Although
slow glycolysis and oxidative phosphorylation are considerably more efficient than fast
glycolysis, the relatively slow rate of ATP production dictates that aerobic mechanisms can only
supply energy for low intensity exercise; however, aerobic mechanisms can oxidize
carbohydrate, fat, and --to a lesser extent-- protein sources to provide ATP during long periods of
physical activity.
As discussed previously, endurance training results in an increase in oxidative enzymes
and mitochondrial density in type I and type II muscle fibers. Strength training may result in
increases of ATP and PCr concentration within muscle cells (192;193), although some
controversy exists as to whether the concentration increases or whether there is simply an
increase in proportion to muscle fiber hypertrophy. Regardless, endurance and resistance training
result in an increase in the corresponding muscle fiber cross sectional area (173;194;195). Type
II fibers tend to undergo greater hypertrophy than type I fibers in response to training, and
training may cause a shift in the proportion of type II fibers from type IIb toward type IIa (196).
Training also influences glycogen storage in skeletal muscle, which may play a role in whole
body glucose disposal (169;197;198). In the context of these somewhat divergent metabolic and
functional adaptations, it is not surprising that the molecular mediators of skeletal muscle
adaptations to endurance and resistance training are quite different (199).
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Molecular Mediators of Skeletal Muscle Adaptations to Exercise
Endurance training primarily causes an increase in AMPK concentration and activity.
AMPK activates downstream targets resulting in greater energy production capabilities of the
cell (200). In addition to its role in contraction-mediated GLUT4 translocation and glucose
metabolism, AMPK plays a role in fatty acid synthesis and oxidation. As early as 1973, kinasedependent phosphorylation of acetyl-CoA carboxylase (ACC) was demonstrated in rat hepatic
cells (201). 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) has been used to activate
AMPK in skeletal muscle to determine the role of AMPK in fat oxidation. Merrill et al. (202)
found that AICAR activated AMPK, inactivated ACC, and decreased malonyl-CoA content in
perfused rat hindlimbs that led to 2.8 fold increase in fat oxidation. Similar results have been
demonstrated in isolated rat skeletal muscle (203). Other groups have suggested a link between
AMPK activity and increased fatty acid oxidation during muscle contraction in rats (204-206)
and humans (207;208).
In humans, type 2 diabetes is often treated with thiazolidinediones (TZDs), which are
ligands for peroxisome proliferator-activated receptor gamma (PPARγ). Activation of PPARγ
and subsequent gene activation appears to enhance insulin sensitivity (209); however, TZDs may
also exert their effects independently of PPARγ-regulated gene transcription by activating the
AMPK signaling pathway (210). Coletta et al. found that treatment with pioglitazone
significantly increased plasma adiponectin and decreased plasma FFA levels in patients with
type 2 diabetes. Furthermore, AMPK and ACC phosphorylation increased with a concomitant
increase in insulin stimulated glucose disposal (211). A similar study found that 3 months of
treatment with rosiglitazone normalized basal AMPK activity and partially restored basal rates of
fatty acid oxidation in patients with type 2 diabetes. (212). Metformin, another drug used for the
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treatment of type 2 diabetes, has also been shown to increase AMPK activation in skeletal
muscle (213;214) and decrease insulin resistance through similar mechanisms (215;216).
Activation of PPARγ co-activator 1 alpha (PGC-1α) by AMPK is a key step whereby
AMPK increases the oxidative capabilities of skeletal muscle. PGC-1α coactivates nuclear
respiratory factors-1 and -2 (NRF-1 and NRF-2), which regulate mitochondrial transcription
factor A (Tfam) (217). Tfam lies upstream of several mitochondrial DNA (mtDNA) gene
products and is responsible for mtDNA transcription. AMPK activation by AICAR (218;219)
and exercise (220-222) have resulted in a concomitant increase in PGC-1α activation and
mitochondrial biogenesis in multiple models. Mitochondria provide most of the energy
consumed by a cell (50) and increased mitochondrial density is related to improved endurance
performance (223). Furthermore, PGC-1α has been shown to increase in mitochondrial oxidative
enzymes in type I and type II skeletal muscle fibers of transgenic mice, suggesting that PGC-1α
causes a phenotypic shift in muscle fibers towards having higher oxidative capabilities (224). It
has been demonstrated that individuals with type 2 diabetes have a low proportion of type 1
muscle fibers (225), smaller mitochondria, and reduced mitochondrial enzyme activity (226228), leading to the hypothesis that mitochondrial dysfunction may contribute to insulin
resistance; however, some groups contest this finding (229;230). Nonetheless, multiple studies
indicate that decreased PGC-1α expression is related to insulin resistance in humans (231-234).
AMPK
Activation of the AMPK signaling pathway and subsequent changes in skeletal muscle by
endurance exercise have been extensively studied in animals and humans. Acute endurance
exercise has been shown to cause increased GLUT4 translocation (235), increased AMPK α2
expression, and decreased blood glucose concentrations in type 2 diabetics (236). AMPK
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activation by endurance exercise may depend on several factors including the intensity of the
exercise and prior training. Chen and coworkers (237) obtained muscle biopsies from the vastus
lateralus of 8 men at rest and after three 20-minute exercise sessions at low, medium, and high
intensity. AMPK α2 activity increased 5-fold from low intensity (~40% VO2peak) to medium
intensity (~59% VO2peak), and continued to increase at high intensity (~79%VO2peak).
Additionally, glucose clearance increased as the intensity of exercise increased, and fat oxidation
increased from rest to medium intensity. Similarly, it has been suggested that obese and diabetic
individuals may need to exercise at higher intensities to elicit the same AMPK signaling
response present in lean individuals after an acute exercise bout. Sriwijitkamol et al (238) found
that low- and moderate-intensity exercise significantly lowered blood glucose concentration in
subjects with type 2 diabetes but not lean and obese subjects. Furthermore, low- and moderateintensity exercise increased AMPK phosphorylation in lean subjects, while only moderateintensity exercise increased AMPK phosphorylation in obese subjects and type 2 diabetics. To
determine the effect of previous training on AMPK activation, Coffey and colleagues (239)
observed the AMPK and mTOR signaling response to endurance and resistance exercise in
trained individuals. Cycling for 1 hour at 70% VO2peak caused a significant increase in AMPK
phosphorylation in resistance-trained individuals, but not endurance-trained individuals.
Additionally, resistance exercise caused a significant increase in AMPK phosphorylation in
endurance-trained individuals, indicating that prior training may affect the signaling response to
acute exercise.
It has been demonstrated that long-term endurance training can restore abnormalities in
the AMPK signaling pathway observed in obese Zucker rats (240). Additionally, endurance
training improved whole-body insulin sensitivity in high-fat fed rats (241). Lessard and
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colleagues (242) demonstrated that rats bred for high endurance running capacity had improved
insulin sensitivity and lower fasting plasma glucose and triglyceride levels than low endurance
capacity rats. Endurance training also increases GLUT4 protein content in rats (104;243) and
obese Zucker rats (244). Furthermore, endurance training increases muscle PGC-1α and rescues
high fat feeding-induced mitochondrial dysfunction in mice (245).
Copious studies have been published demonstrating the beneficial effects of endurance
training for humans with insulin resistance and type 2 diabetes. Training periods typically range
from 2 to 9 months and employ various training modalities and intensities, although as little as 1
week of training has been shown to be beneficial (246). Eight weeks of cycle ergometer training
at approximately 65-70% VO2peak significantly increased mitochondrial FA oxidation and
glucose tolerance in obese humans (247). Similarly, Venables and Jeukendrup (248)
demonstrated that 4 weeks of endurance training increased FA oxidation rates by 44% and
increased whole-body insulin sensitivity index by 27%. Other groups have demonstrated that the
increase in FA oxidation in obese subjects is due to endurance training and not weight loss
(249;250). In subjects with type 2 diabetes, 8 weeks of endurance training increased VO2peak
approximately 20% and insulin sensitivity approximately 30% (251). Houmard and colleagues
(103) demonstrated that 14 weeks of training caused a nearly twofold increase in GLUT4 content
in vastus lateralis muscle. Seven weeks of endurance exercise on a cycle ergometer significantly
increased citrate synthase activity, FA oxidation and mitochondrial area in untrained subjects
(252). Coggan et al. (253) demonstrated that 9-12 months of walking or jogging caused a 23%
increase in VO2max and increased the activity of several mitochondrial enzymes. The literature
reviewed in this section highlights the importance of AMPK in mediating the molecular
adaptations to exercise and the subsequent impact on risk factors for the metabolic syndrome.
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mTOR
As discussed previously, resistance exercise is short duration, high intensity exercise that
primarily causes skeletal muscle hypertrophy by increasing protein synthesis and decreasing
protein degradation. The Akt/mTOR signaling pathway is up regulated during skeletal muscle
hypertrophy and has been identified as a major regulator of cell growth (254). mTOR is thought
to be a sensor of substrate availability, particularly amino acids (255;256). The Akt/mTOR
pathway regulates the cellular metabolic response to the availability of substrates and the
presence of insulin and other growth factors (257). Additionally, the Akt/mTor pathway may be
activated by changes in cellular ATP levels (258). Recently, possible roles of mTOR and its
downstream targets in the development and treatment of insulin resistance and the metabolic
syndrome have been elucidated. Decreased ß-cell size and a concomitant decrease in glucosestimulated insulin secretion has been observed in S6 kinase 1 (S6K1) deficient mice (259);
however, Um and colleagues (260) demonstrated that S6K1-/- mice are hypersensitive to insulin
and are protected from diet-induced obesity. Furthermore, it has been demonstrated that
inhibition of the mTOR signaling pathway by the immunosuppressive drug rapamycin results in
increased insulin-stimulated glucose transport (261), suggesting that mTOR plays a role in
glucose disposal and insulin resistance.
mTOR is a 289 kDa protein that belongs to the phosphoinositide-3 kinase (PI3K)-related
kinase family (262). mTOR nucleates 2 distinct protein complexes, termed mTORC1 and
mTORC2. mTORC1, which is sensitive to rapamycin and nutrient signaling, contains regulatory
associated protein of mTOR (RAPTOR), G-protein beta-like protein (GßL), protein rich Akt
substrate 40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting protein (Deptor).
mTORC2, sometimes referred to as the rapamycin-insensitive complex, contains mammalian
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stress-activated protein kinase interacting protein (mSIN1) and rapamycin-insensitive companion
of mTOR (RICTOR) instead of RAPTOR (263). The activity of mTOR and its downstream
targets are regulated by a complex signaling pathway that can be activated through several
mechanisms, primarily via insulin signaling. Phosphorylation of IRS proteins by insulin and
insulin-like growth factors (IGFs) causes association of IRS-1 with PI3K. This association
results in the production of phosphatidylinositol (3,4,5)-triphosphate (PIP3) which activates
PI3K-dependent kinase 1 (PDK1) (264). PDK1 in turn activates Akt, which inactivates tuberous
sclerosis complex 2 (TSC2), an inhibitor of cell growth. Consequent activation of Rheb activates
mTORC1 that phosphorylates downstream targets, including S6K1 and eukaryotic initiation
factor 4E (eIF3E)-binding protein 1 (4E-BP1) (265). Phosphorylation of 4E-BP1 by mTORC1
inhibits its binding to eIF4E allowing eIF4E to promote cap-dependent translation (266).
Similarly, S6K1 activation results in increased cap-dependent translation and elongation, mRNA
biogenesis, and ribosomal protein translation (262).
Considering the central role of mTOR in the energy regulation of mammalian cells, it is
no surprise that mTOR is an important mediator of the metabolic responses to exercise. A single
bout of resistance exercise can cause an transient increase in protein synthesis of up to 115%
(177). This increase in protein synthesis in response to acute resistance exercise appears to occur
in an mTOR-dependent manner (267). Baar and Esser (268) demonstrated that electrical
stimulation mimicking resistance training resulted in increased activity of S6K1, which
correlated with hypertrophy of extensor digitorum longus and tibialis anterior in rats. Nader and
Esser (269) performed a similar investigation employing high and low frequency electrical
stimulation of tibialis anterior and soleus muscles. High frequency stimulation produced a
transient increase in Akt phosphorylation and a long-term increase in S6K1 activation. A later
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investigation by Atherton and coworkers (270) demonstrated that high-frequency electrical
stimulation of isolated rat muscle caused an immediate increase in mTOR and Akt
phosphorylation. In trained and untrained humans, acute resistance exercise causes increased
myofibrillar protein synthesis with a concomitant increase in mTOR and S6K1 activation (271).
Considerable evidence suggests that resistance training is an effective method for
ameliorating insulin resistance in humans (159;164-167); however, little is known about the
potential role of mTOR in mediating the positive effects of resistance training in insulin resistant
individuals. Recently, Izumiya and colleagues (272) generated a transgenic mouse expressing a
constitutively activated form of Akt1. Two weeks of Akt1 activation led to a significant increase
in type IIb muscle fiber cross-sectional area in the gastrocnemius. In addition, Akt1 activation in
high fat/high sucrose fed mice led to a 44% reduction in subcutaneous fat pad mass as well as
normalization of fasting blood glucose levels, insulin levels, and glucose uptake. These results
suggest a possible mechanism by which resistance training and the consequent activation of the
Akt/mTOR signaling pathway may ameliorate the metabolic syndrome.
Summary
The prevalence of metabolic disorders such as obesity, diabetes, and the metabolic
syndrome is on the rise. Left untreated, these conditions can lead to cardiovascular disease and
other complications. Exercise has been considered a cornerstone of diabetes prevention and
treatment for decades. Increased activity levels can positively alter body composition, blood
lipids, blood pressure, and other risk factors for the metabolic syndrome. At the molecular level,
exercise activates intracellular signaling pathways that mediate the skeletal muscle adaptations to
exercise. Activation of the AMPK pathway leads to mitochondrial biogenesis and increases
GLUT4 protein expression and translocation, while mTOR increases protein synthesis. Several
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studies have demonstrated that activation of the AMPK signaling pathway in response to
endurance and resistance training has a positive impact on insulin sensitivity in humans;
however, the exact mechanisms leading to increased insulin sensitivity in response to mTOR
activation have yet to be elucidated in humans.
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ABSTRACT
The prevalence of the metabolic syndrome is increasing at an alarming rate. Endurance exercise
has been considered a cornerstone of diabetes treatment and prevention for decades, but the
benefits of resistance training are less clear. Ten subjects with the metabolic syndrome (MS
subjects; 5 male, 5 female) and 9 sedentary controls (4 male, 5 female) were recruited to undergo
8 weeks of resistance training. Euglycemic hyperinsulinemic clamps were performed before and
after training to quantify insulin sensitivity. Muscle biopsies were taken from the vastus lateralus
and changes in muscle fiber composition, muscle adenosine monophosphate-activated protein
kinase (AMPK), mammalian target of rapamycin (mTOR), glucose transporter protein 4 and 5
(GLUT4 and GLUT5), and ATP synthase were quantified. Additionally, functional capabilities
(isometric strength and VO2max) were measured before and after training. After training, strength
and stamina increased by 13% and 35% in both groups, respectively. Insulin sensitivity reflected
by glucose infusion rate did not improve in MS subjects after training (3.3 mg/kg.min ± 1.3
before training vs.3.1 ± 1.0 post); however, the increase in insulin sensitivity was statistically
significant in controls (p<0.01, 7.0 ± 2.0 pre vs. 8.7 ± 3.1 post). Controls increased muscle
expression of p-AMPK (+50.0%) and ATP synthase (+63.0%) to a greater extent than MS
Subjects (+13.0% and 25.0%, respectively); however, MS subjects increased expression of pmTOR to a greater extent (57.0% vs. 32.0%, respectively). These data indicate that while
resistance training improved functional capabilities in MS subjects, insulin sensitivity was not
improved, possibly due to inhibition of the AMPK signaling pathway.

Key Words: METABOLIC SYNDROME, RESISTANCE TRAINING, ADENOSINE
MONOPHOSPHATE ACTIVATED PROTEIN KINASE, MAMMALIAN TARGET OF
RAPAMYCIN, GLUCOSE TRANSPORT PROTEINS
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INTRODUCTION
The prevalence of metabolic disorders such as obesity, the metabolic syndrome and
diabetes is widespread and is continuing to rise. Exercise is considered one of the cornerstones of
diabetes prevention and treatment. Both endurance and strength training are effective for
ameliorating insulin resistance and improving blood sugar control (164); however, the skeletal
muscle adaptations and the signaling pathways through which these adaptations occur appear to
be dependent upon the type of exercise performed (199).
An array of physiological adaptations occur in response to endurance training. Endurance
training can cause an increase in the oxidative capacity of both Type 1 (slow twitch, red) and
Type II (fast twitch, white) muscle fibers primarily by increasing oxidative enzyme content and
upregulating mitochondrial biogenesis (168;273). These adaptations enhance the efficiency of
energy production from substrate use (fatty acids and glucose). 5-adenosine monophosphateactivated protein kinase (AMPK) is a key energy sensor in most cells and is activated during
endurance exercise due to an increase in the adenosine monophosphate-adenosine triphosphate
ratio (89). Activation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a
downstream target of AMPK, coactivates nuclear respiratory factors-1 and -2 (NRF-1 and NRF2), which regulate mitochondrial transcription factor A (Tfam). In turn, Tfam is responsible for
regulating mitochondrial DNA gene products (217). Endurance exercise also increases glucose
transport protein-4 (GLUT4) expression in skeletal muscle (198). Activation of the AMPK
signaling pathway may contribute to GLUT4 translocation to the plasma membrane (83).
Resistance training results in skeletal muscle hypertrophy, particularly in Type II fibers,
with a concomitant increase in muscular strength (274). Muscle fiber hypertrophy occurs via an
increase in protein synthesis and a decrease in protein degradation, which may occur in a fiber
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type-specific manner (275). Increased protein synthesis occurs through a cell signaling pathway
involving mammalian target of rapamycin (mTOR). mTOR integrates intracellular and
extracellular signals from growth factors (insulin, insulin-like growth factors), substrate
availability and cellular energy levels to regulate metabolic responses within the cell (262).
Upstream of mTOR, insulin receptor proteins interact with phosphoinositide 3 kinase (PI3K) in
response to insulin resulting in the production of phosphatidylinositol (3,4,5)-triphosphate (PIP3).
PIP3 activates PDK1 that in turn activates Akt. Akt activation eventually phosphorylates mTOR,
a protein that nucleates two mult-protein complexes, mTORC1 and mTORC2. mTORC1
phosphorylates 70-kDa S6 protein kinase (S6K1) and dephosphorylates 4E binding proteins
resulting in increased protein synthesis (262). Animal and human studies indicate that acute
resistance exercise and training result in increased mTOR activation and increased protein
synthesis (269;271). Recently, a transgenic mouse model expressing a constitutively activated
form of Akt1 has demonstrated a potential link between mTOR activation and improved
metabolic parameters. In this model, Akt1 activation decreased fat pad mass and normalized
fasting blood glucose levels, insulin levels, and glucose uptake with a concomitant increase in
type IIb muscle fiber size in high fat/high sucrose fed mice (272).
The aim of the current study was to quantify the effectiveness of a resistance training
program for increasing the skeletal muscle expression of molecular mediators that may be
beneficial for individuals with the metabolic syndrome. Sedentary subjects (9 control, 10
metabolic syndrome) volunteered for 8 weeks of supervised resistance training. Muscle biopsies
were obtained from the vastus lateralus prior to and after completion of the resistance training
program. Changes in molecular mediators of skeletal muscle adaptations including AMPK and
mTOR expression were measured. Additionally, glucose transport protein expression was

42

measured, and muscle fiber-type specific changes were quantified. Furthermore, insulin
sensitivity was assessed using the euglycemic-hyperinsulinemic clamp technique and related to
the skeletal muscle adaptations to training.
MATERIALS AND METHODS
Subject Selection. Nineteen subjects were recruited to undergo 8 weeks of supervised
resistance exercise. The research protocol and the consent documents were approved by the East
Tennessee State University Institutional Review Board. Each subject gave signed informed
consent. The exercise program was performed at the ETSU Exercise and Sports Sciences
Laboratory with students from the Department of Kinesiology. Subjects were divided into 2
groups based on the inclusion and exclusion criteria presented in Table 1. Ten MS subjects and 9
controls were able to complete the training and planned measurements.
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Metabolic Syndrome
“MS Subjects”

Sedentary Controls
“Controls”

Inclusion
Age 18-55

Exclusion

Inclusion
Age 18-55

Exclusion

2

Obese: BMI ≥ 30
kg/m2

BMI < 30 kg/m2

Non-obese: BMI <
30 kg/m2

BMI ≥ 30 kg/m2

3

Family history of
type 2 diabetes

Current diabetes:
Fasting blood
glucose ≥126 mg/dL

Sedentary – less
than 1.5 hours
exercise/week

Family history of
type 2 diabetes

4

Visceral obesity
waist ≥40 inches for
males, ≥35 inches
for females

Acute or chronic
illness that would
impair participation
in training

Acute or chronic
illness that would
impair participation
in training

5

Clinical coronary
disease

Current diabetes or
impaired fasting
blood glucose ≥110
mg/dL

6

Uncontrolled
hypertension

1

Table 1
Inclusion and exclusion criteria for MS subjects and controls.

Exercise Protocol. Training consisted of large muscle mass free weight exercises (Table
2). A light familiarization and baseline measurement period was followed by 4 weeks of high
volume, low intensity training (Phase I). The intensity of the exercise (based on an estimate of
relative repetition maximum) increased approximately 10% each week for the first 3 weeks,
followed by a 10% drop in intensity from week 3 to week 4 to allow for recovery. During Phase
II (weeks 5-8), volume decreased and intensity increased to allow for greater strength gains.
Similar to Phase I, intensity increased approximately 10% week to week and was decreased by
10% during week 8 to allow for recovery. All sets (warm up and target sets) were recorded and
calculated as total volume load (sets x reps x weight). Subjects were instructed to maintain
weight during the study period. Blood pressure, blood lipids, body composition, and strength and
endurance measurements were taken before and after training.
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Phase I (Weeks 1-4) 10 repetitions x 3

1

Monday
Squats

Tuesday
Bent-legged
Situps

Wednesday
Shoulder
Shrugs

Thursday
Bent-legged
Situps

Friday
Squats

Saturday
Vertical Jumps

2

Bench Press

Supine
Windshield
Wipers

Mid-thigh Pulls

Supine
Windshield
Wipers

Bench Press

Stretch

3

Seated
Dumbbell
Press

Stretch

Stiff-legged
Deadlifts

Stretch

Seated
Dumbbell
Press

4

Front Raises

Bentover rows

5

Front Raises

Bicep Curls

Phase II (Weeks 5-8) 5 repetitions x 3
Monday

Tuesday

Wednesday

Thursday

Friday

Saturday

1

Squats

Shoulder
Shrugs

Baskethangs
3x10

Shoulder
Shrugs

Squats

Stretch

2

Squat Press

Mid-thigh Pulls

Supine
Windshield
Wipers 3x10

Mid-thigh Pulls

Squat Press

3

Dumbbell
Incline Press

Stiff-legged
Deadlifts

Stretch

Stiff-legged
Deadlifts

Dumbbell
Incline Press

4

Lateral Raises

Upright Row

Upright Row

Lateral Raises

Assisted Pullups

Assisted Pullups

5

Table 2
List of exercises performed during the eight weeks of resistance training. Weeks 1-4 were high volume training
designed to facilitate gains in fitness and strength-endurance. Weeks 5-8 were high intensity and low volume training
emphasizing strength.

Subject Assessments. Several assessments related to body composition were measured at
baseline and after 8 weeks of resistance training (Table 3). Subject height was measured to the
nearest 0.1 cm using a stadiometer and body mass was measured to the nearest 0.1 kg using an
electronic scale. Body composition was measured by air displacement plethysmography
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(BodPod, Concord, CA). Additionally, a 7-site skinfold measurement was performed on each
subject (Lange Skinfold Caliper, Beta Technology Inc, Cambridge, MD). Waist circumference
was measured just above the iliac crest to the nearest 0.1 cm.
MS Subjects

Controls

(5 male, 5 female)

(4 male, 5 female)

Age

45.0 ± 8.6

36.4 ± 12.2

Body Mass (kg)

99.5 ± 13.8

69.2 ± 16.2

BMI (kg/m2)

33.7 ± 3.0

24.3 ± 3.6

Resting Systolic
Blood Pressure
(mmHg)

131 ± 20

113 ± 10

Resting Diastolic
Blood Pressure
(mmHg)

82 ± 9

77 ± 10

103.3 ± 11.5

88.6 ± 12.8

Fasting Blood
Sugar (mg/dL)

Table 3
Subject characteristics at baseline

Strength Testing. Strength was assessed isometrically using a custom built lifting rack.
Prior to the assessment, all subjects performed a standardized warm up consisting of 25 jumping
jacks followed by a warm up set of mid-thigh pulls (20kg) and 3 sets of 5 repetitions with either
40kg (women) or 60kg (men). The lifting rack was set so that the subjects pulled from the midthigh pull position used in training (knee angle 120o – 135o, hip angle 170o – 175o). The subjects
performed 2 warm up isometric mid-thigh pulls (50% and 75% effort), proceeded by 2 maximum
effort pulls. Additional pulls were performed if the pull was preceeded by a countermovement, or
if the peak force of each pull differed by ≥250N as measured on a force plate (Rice Lake
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Weighing Systems, Rice Lake, WI, USA) with a sampling rate of 1000Hz. Data were collected
and analyzed for peak force (PF) and rate of force development (RFD) using custom Labview
8.6 software (National Instruments, Upper Saddle River, NJ).
Endurance Testing. Endurance was measured using a Monark Ergomedic 874E cycle
ergometer (Monark Exercise AB, Vansbro, Sweden). After a brief warm up period with no
resistance, a graded exercise test was performed. Stage 1 began with 0.5 kg of resistance, and the
resistance was increased 0.5 kg every 2 minutes until a resistance of 1.5 kg was reached. The
resistance was then increased 0.2 kg every 2 minutes until the subject could no longer continue.
Expired air was analyzed using a TrueOne 2400 Metabolic Measurement System (ParvoMedics,
Sandy, Utah, USA). Heart rate, VO2max (expressed as ml/kg/min), respiratory exchange ratio
(RER) and time to exhaustion were recorded.
Muscle Biopsies. Percutaneous needle biopsies of vastus lateralis were performed after
an overnight fast and 2 hours of quiet recumbency as previously described (75;276). Briefly,
after local lidocaine anesthesia, a 7-10 mm skin incision was made and a Bergstrom-Stille 5 mm
muscle biopsy was introduced through the fascia, and under suction a 50-100 mg specimen was
obtained. After quickly blotting, the sample was divided in half, with one piece frozen
immediately in liquid nitrogen for later analysis, and the second piece mounted on cork and
quickly frozen in a slurry of isopentane cooled in liquid nitrogen (277). The cork-mounted piece
is later sectioned on a cryostat (Leica, Wetzlet, Germany) for evaluation of fiber type
composition, fiber cross sectional areas, and immunohistochemistry.
Euglycemic Hyperinsulinemic Clamp. Immediately following the muscle biopsy, a
euglycemic hyperinsulinemic clamp was performed. After a 2-hour baseline period, a single
infusion of regular insulin was performed at 15 mU/m2 for 3 hours in order to achieve a
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physiological insulin concentration of about 40 μU/mL and a stable glucose infusion rate to
quantify insulin sensitivity (58;278;279).
Quantification of Muscle Fiber Type Composition and Fiber Size. Fiber composition was
determined using methods described by Behan et al. (280). Muscle sections were stained for
light microscopy in a 2-step method using commercial monoclonal antibodies to fast and slow
isoforms of myosin. After acetone fixation and incubation with 20% normal rabbit serum, the
slow myosin antibody (Sigma clone NOQ7.5.4D) was applied, followed by a peroxidaseconjugated rabbit anti-mouse IgG antibody. The fast myosin antibody (Sigma clone MY-32
alkaline phosphatase conjugate) was then applied after another incubation with normal rabbit
serum as described by Behan (281). Slides are finally alcohol dehydrated, cleared with xylene,
and preserved in synthetic medium. This technique allows discrimination of type 1, type IIa,
and type IIx. All sections were coded and then quantified independently by 3 observers who
were unaware of which subject or treatment the image represented. Fiber size was quantified by
numbering at least 100 identifiable fibers on color images from a camera-equipped microscope.
Muscle specimens were cut perpendicular to the fiber direction using a Leica CM3050 S cryostat
and pre-training and post-training sections were placed on the same slide in the same order for
each subject. The digital images obtained included a key of a known dimension and were coded
and submitted to a technician for quantification. In each image, type 1 fibers, type IIa, and type
IIx fibers had their 2 major diameters measured (d1 and d2) and the area was estimated by using
the smaller of the 2 diameters as described by Dubowitz (277).
Preparation of Muscle Homogenates. Briefly, a small piece of muscle was removed from
the -80oC freezer and slowly thawed on ice. Muscle homogenate was prepared by placing 25-50
mg muscle in 500 µL 0.25 M sucrose, 20 mM HEPES, pH 7.4, containing protease inhibitors
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(Halt Protease Inhibitor Cocktail Kit from Pierce), and homogenized with two 30 second bursts
of a hand-help homogenizer (Pellet Pestle Motor from Kontes).
Mitochondrial Markers. Confocal microscopic assessment of specific fluorescent
labeling of several proteins in normal human muscle sections were performed using methods
previously described (75). All evaluations of changes in expression of these mitochondrial
markers were performed on slides containing both the pre- and post-training muscle sample
transverse sections as described recently (76). A mixture of antibodies to 5 different
mitochondrial components were purchased from MitoSciences (No. MS604). These antibodies
are directed against Complexes I, II, III, and IV, and to ATP synthase subunit alpha. The
principle component used for these analyses was ATP synthase. In general, 4-20% gradient gels
(Thermo Scientific, Rockford, IL) were loaded with 7.5 µg protein from muscle homogenates.
Blots were blocked with 0.25% non-fat dry milk.
Key regulatory Protein Kinases (AMPK, mTOR). Comparison of expression of these
proteins were also quantified in immunoblots as previously described (282). Antibodies for
AMPK, phospho-AMPKα1, mTOR, and phospho-mTOR were purchased from Cell Signaling
Technology (#2531, #2531, #2972, #2971). For AMPK and phospho-AMPK, samples
containing 5 µg protein from muscle homogenates were applied to 10% polyacrylamide gels.
Immunoblots were blocked with 5% non-fat dry milk. Gradient gels 3-8% (Invirogen) were used
for mTOR and phospho-mTOR immunoblots. These samples were 10 µg per lane and blocking
was 0.25% non-fat dry milk.
Fiber-Specific Expression of Principle Muscle Hexose Transporters (GLUT4 and
GLUT5). The techniques for quantifying these glucose transporters were described previously
(75;76). Affinity-purified rabbit antibodies against hGLUT5 (GT52-A) were purchased from
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Alpha Diagnostics (San Antonio, TX). GLUT4 antibodies (AB1049, goat anti-human) were
purchased from Chemicon. Determining the fiber type that stains more intensely requires the use
of fluorescent tagged antibodies that can be mixed together and evaluated with either the
confocal microscope or a fluorescent microscope with multiple filters. We used both types of
microscopes, but the confocal microscope was the primary device for these studies.
Statistics. All data are displayed as mean ± SE. Paired t-test was used for comparisons
before and after training. Effect size correlations were calculated using Cohen’s d (Table 4)
(283). Relationships between select variables were assessed using a Pearson correlation
coefficient. Statistical procedures were performed using SigmaStat version 3.11 from Systat
Software (San Jose, California).

Trivial

<0.1

Small

0.1-0.3

Moderate

0.3-0.5

Large

>0.5

Table 4
Cohen's d Effect Sizes

RESULTS
Anthropometrics, Functional Capabilities and Volume Load. Eight weeks of resistance
training had a positive impact on body composition (Table 5). Overall, training had little effect
on body mass or fat mass; however, the percentage change in body mass was strongly correlated
with the percent gain in lean body mass (LBM) in both groups (r=0.532). Although the increase
in LBM was relatively small (d=0.122), the change was statistically significant in both groups.
The decrease in waist circumference was statistically significant (p = 0.022); however, the effect
size was small in metabolic syndrome and controls (-0.375 and -0.319, respectively). Training
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tended to decrease body fat percentage in both groups, but the change was only statistically
significant in metabolic syndrome (p=0.010). The sum of the skinfold thickness measured at 7
sites also tended to decrease in both groups (-1.5% in metabolic syndrome and -2.4% in
controls), but this decrease was not statistically significant.
BMI (kg/m2)

Body Mass (kg)

Waist Circumference (cm)

Pre

Post

d

Pre

Post

d

Pre

Post

d

All (n=19)

85.2 ±
21.3

85.1 ±
21.3

-0.006

29.2 ±
5.8

29.5 ±
5.8

0.043

105.1 ±
14.4

102.2* ±
15.6

-0.199

MS
Subjects
(n=10)
Controls
(n=9)

99.5 ±
13.8

99.3 ±
14.3

-0.02

33.7 ±
3.0

34.0 ±
3.3

0.099

115.9 ±
5.5

113.5 ±
8.0

-0.375

69.2 ±
16.2

69.2 ±
16.1

0.004

24.3 ±
3.6

24.5 ±
3.3

0.057

93.1 ±
11.0

89.7 ±
11.7

-0.319

Pre

Fat Mass (kg)
Post

d

Pre

LBM (kg)
Post

d

Pre

% Body Fat
Post

All

31.1 ±
13.9

31.0 ±
14.0

-0.009

52.8 ±
10.4

54.1** ±
10.6

0.122

35.6 ±
10.2

34.9* ±
9.9

-0.066

MS
Subjects

41.4 ±
8.1

41.3 ±
8.4

-0.006

56.8 ±
9.5

58.0* ±
10.1

0.127

42.2 ±
5.4

41.7** ±
5.3

-0.102

Controls

19.8 ±
9.3

19.5 ±
9.1

-0.024

48.4 ±
9.9

49.7** ±
9.9

0.141

28.3 ±
9.4

27.5 ±
8.4

-0.095

d

Table 5
Body mass, BMI, waist circumference, fat mass, lean body mass, and percent body fat (mean±SD) for all subjects before and
after eight weeks of resistance training. d=Cohen's d effect size. *p≤0.05 **p≤0.01

Overall, VO2max increased 10.3% and time to exhaustion increased approximately 35% in
both groups (Table 6). The increase in VO2max was statistically significant in both groups, and
both groups achieved relatively large effect sizes (d=0.819 in MS subjects and 0.535 in controls).
The increase in time to exhaustion was also statistically significant (p<0.001). MS subjects
improved in isometric peak force (IPF) and rate of force development (RFD) after training.
Controls tended to increase in IPF and RFD, but the increase was not statistically significant.
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Isometric Peak Force (N/kg2/3)
Pre
All
MS
Subjects
Controls

134.5 ±
37.1
135.0 ±
39.5
133.9 ±
36.7

Rate of Force Development (N/s)

VO2max (mL/kg/min)

Post
148.8** ±
41.5

d
0.374

Pre
3061 ±
1745

Post
3716* ±
2180

d
0.341

Pre
27.0 ±
5.4

Post
29.6** ±
5.7

d
0.482

153.1** ±
36.3

0.503

2937 ±
2166

3763* ±
2480

0.374

23.3 ±
3.1

26.2** ±
4.1

0.819

143.5 ±
49.3

0.234

3184 ±
1321

3664 ±
1957

0.305

31.0 ±
4.5

33.4* ±
4.9

0.535

Table 6
Functional capabilities. Isometric peak force and rate of force development were measured using a custom built force
rack and a force plate (Rice Lake Weighing Systems, Rice Lake, WI, USA) sampling at 1000Hz. VO2max was
measured on a Monark Ergomedic 874E cycle ergometer (Monark Exercise AB, Vansbro, Sweden).

Volume load calculated as sets*reps*weight was tracked for each subject. Average
weekly volume load is shown in Figure 1 below. Total volume load was 16% higher in MS
subjects than in controls (93796 kg ± 32153 and 80737 kg ± 27022, respectively); however, this
difference was not statistically significant. Isometric peak force measured prior to training and
total volume load were strongly correlated (r=0.681).
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Figure 1
Average weekly volume load. Volume load is an estimate of total work performed, and is a
product of the sets, repetitions, and load lifted.

Blood Lipids, Glucose, Insulin, and Euglycemic Hyperinsulinemic Clamp. Circulating
levels of triglycerides, HDL, and LDL cholesterol were measured at baseline and after training.
Triglyceride levels were 114.2 ± 52.3 in controls and 198.4 ± 173.4 in MS subjects at baseline.
Controls had HDL and LDL cholesterol concentrations of 48.0 ± 11.0 and 87.3 ± 16.4 at
baseline, while MS subjects had low HDL cholesterol (39.8 ± 9.0) and elevated LDL cholesterol
(112.4 ± 41.3). Triglycerides and total cholesterol tended to be lower in both groups after
resistance training, but the differences were not statistically significant and the effect sizes were
small (d=-0.158 and -0.148, respectively).
Insulin sensitivity was assessed using the euglycemic hyperinsulinemic clamp technique
described in the methods. Fasting insulin was higher in MS subjects both at baseline and after
training (Table 7). Fasting insulin decreased 22% in controls after training (p < 0.05). Fasting
blood glucose was higher before and after training in MS subjects. Although fasting blood
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glucose tended to be lower after training, the effect size was small (d =-0.123). As shown in
Table 7 and Figure 2, MS subjects showed marked insulin resistance at baseline (glucose
infusion rate 3.3 ± 1.3), and training had little effect on glucose infusion rate. In contrast,
controls demonstrated normal insulin sensitivity prior to training (GIR 7.0 ± 2.0), and glucose
infusion rate increased 25% after resistance training. The increment in insulin concentration
achieved by the insulin infusion was similar in both groups before and after training. The insulin
concentration increment averaged 52 and 52 µU/ml for MS subjects and controls at baseline and
52 and 49 µU/ml post-training, respectively.

Fasting Insulin (µU/mL)

Fasting Blood Glucose
(mg/dL)

Achieved Insulin
Concentration (µU/mL)

Glucose Infusion Rate
(mg/kg.min)

Pre

Post

d

Pre

Post

d

Pre

Post

d

Pre

Post

d

All

11.3 ±
8.0

10.2*
± 7.6

-0.147

96.3 ±
14.0

100.0
± 10.9

0.302

62.9 ±
17.1

60.9 ±
14.3

-0.136

5.1 ±
2.5

5.7* ±
3.6

0.226

MS
Subjects

14.7 ±
9.6

13.9 ±
8.3

-0.087

103.3
± 11.5

101.9
± 12.4

-0.123

66.1 ±
17.2

66.3 ±
15.4

0.011

3.3 ±
1.3

3.1 ±
1.0

-0.193

Controls

7.6 ±
3.5

6.0** ±
3.9

-0.44

88.6 ±
12.8

97.9**
± 9.0

0.893

59.4 ±
17.2

54.8 ±
10.6

-0.34

7.0 ±
2.0

8.7** ±
3.1

0.681

Table 7
Markers of insulin resistance. Fasting insulin and fasting blood glucose were measured after an overnight fast. A single infusion
of regular insulin was performed at 15 mU/m 2/min for three hours in order to achieve a physiological insulin concentration of
about 40 μU/mL. Glucose was infused at a variable rate to maintain euglycemia. After training, fasting insulin concentration
tended to decrease in both groups. The decrease was only statistically significant in controls (p<0.01). Glucose infusion rate
(GIR) increased significantly in controls after training (p=0.03), indicating increased insulin sensitivity; however, GIR was
unchanged in MS subjects after training.
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Figure 2
Glucose infusion rate (GIR). After a 2-hour baseline period, a single infusion of regular insulin was performed at 15 mU/m 2/min for
three hours in order to achieve a physiological insulin concentration of about 40 μU/mL. Glucose was infused at a variable rate to
maintain euglycemia. The rate of steady state glucose uptake in the last 30 minutes reflects insulin sensitivity. MS subjects
demonstrated lower GIR than controls before and after eight weeks of resistance training. GIR tended to be lower in MS subjects
after training; however, the decrease was not statistically significant. Controls demonstrated a statistically significant increase in GIR
due to training (p<0.05).

Skeletal Muscle Fiber Composition and Size. Percutaneous muscle biopsies of the vastus
lateralus were performed at baseline and after training, and muscle fiber composition was
determined using monoclonal antibodies for fast and slow myosin. As shown in Figure 3, MS
subjects had a lower percentage of type I muscle fibers than controls at baseline (36.3% ± 10.2%
vs. 50.0% ± 17.7%, p = 0.03). Percentage of type 1 fibers was unchanged after training. Training
tended to cause a shift in fiber composition from type IIx to type IIa; however, the effect was
small (d =0.119) and not statistically significant. Fiber cross sectional area did not change in
either group.
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Figure 3
Muscle fiber type portion. Percutaneous muscle biopsies were taken from the vastus lateralus and muscle sections were stained for
light microscopy using monoclonal antibodies of fast and slow myosin. (A) Fiber type portion for each group at baseline. MS subjects
had fewer type I muscle fibers and tended to have a greater proportion of type IIa/x muscle fibers. (B) Muscle fiber composition for
controls before and after training. Fiber composition tended to shift away from type I fibers and toward type IIx; however, the effect
sizes were relatively small (d= -0.295 for type I fibers and d=0.293 for type IIx fibers). (C) Muscle fiber composition in MS subjects.
Fiber type tended to shift towards type I and type IIa muscle fibers. The increased oxidative capacity of these muscle fibers may be
reflective of the skeletal muscle adaptations elicited by the increased energy demands of training.

Glucose Transport Proteins. Expression of glucose transport proteins GLUT4 and
GLUT5 were also quantified. As shown in Figure 4, MS subjects had slightly higher GLUT4
expression than controls prior to training (2.80 ± 1.41 and 2.38 ± 1.11, respectively). GLUT4
expression increased significantly after training in both groups (p ≤ 0.05). The percent increase
in muscle GLUT4 content was greater in controls than MS subjects (67%, d = 1.634 vs. 36%, d =
0.843, respectively). GLUT5 expression increased significantly in MS subjects (p ≤ .05, d =
1.0512) but was unchanged in controls. The increase in muscle GLUT5 in MS subjects may be
reflective of the higher proportion of type II muscle fibers in these subjects.
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Figure 4
GLUT4 and GLUT5 expression before and after training. (A and B) Representative immunoblots of
GLUT4 and GLUT 5 expression. 5 µg of muscle homogenate was applied to polyacrylamide gel and
probed with antibodies against GLUT4 and GLUT5. (C and D) Changes in GLUT4 and GLUT5 expressed
as femtomoles per 5 µg of muscle homogenate. The increase in GLUT4 due to training was statistically
significant in both groups (p<0.05); however, controls increased to a greater extent than MS subjects
(67.0% and 36.0%, respectively). GLUT5, a fructose transporter protein, was unchanged after training in
controls. GLUT5 increased 21.2% in MS subjects.

AMPK. Total and phospho-AMPK expression were quantified by immunoblot analysis
as shown in Figure 5. Total AMPK expression increased significantly in both groups, with very
strong effect sizes (d = 1.338 in MS subjects and d = 1.77 in controls). Phospho-AMPK
expression increased 50% in controls (p < 0.001, d = 1.924). Phospho-AMPK expression
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increased 13% in MS subjects; however, the increase was not statistically significant and the
effect size was relatively small (d = 0.368).
ATP synthase ATP synthase expression, a marker of mitochondrial enzyme activity,
increased significantly in both groups in response to training. MS subjects had higher ATP
synthase expression at baseline than controls (p=0.112), but training increased ATP synthase
expression by 63% in controls compared to 25% in MS subjects.
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Figure 5
Immunoblot analysis of total AMPK, phospho-AMPK, and ATP synthase expression. (A and B) Representative immunoblots of total
AMPK and phospho-AMPK before and after training. Each lane of total AMPK and phospho-AMPK contained 5 µg of protein from
muscle homogenates and were applied to 10% gels. The pretraining sample is indicated by "A" and the posttraining sample is
indicated by "B." Both groups showed a statistically significant increase in total AMPK expression after eight weeks of resistance
training as indicated in D and E; however, only controls showed a significant increase in phospho-AMPK by paired t-test (p<0.01).
(C) Representative immunoblots of ATP synthase expression. ATP synthase, a marker of mitochondrial biogenesis, was quantified
before and after training. Generally, each lane was loaded with 7.5 µg of protein homogenate and blocked with 0.25% non-fat dry
milk. Both groups showed a statistically significant increase in ATP synthase expression, as indicated in F. Controls tended to
increase to a greater extent than MS subjects (63.6% and 24.6%, respectively).

mTOR. Total and phospho-mTOR, a molecular mediator of protein synthesis, increased
significantly in MS subjects in response to training (Figure 6). While the increase in total mTOR
expression was not statistically significant in controls, total mTOR expression increased 32%
and the effect size was strong (d = 0.772). Total mTOR expression increased 57% in MS subjects
in response to resistance training. Phospho-mTOR expression had a similar response to
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resistance training. Phospho-mTOR increased 55% in MS subjects (d = 1.49, p < 0.01) and 39%
in controls. Again, the effect size was large in controls (d = 0.754), but the increase was not
statistically significant.

Figure 6
Total and phospho-mTOR expression. (A and B) Representative immunoblots of total mTOR and
phosho-mTOR expression before and after training. Each lane contains 10 µg of muscle homogenate
and was applied to 3-8% gradient gels.(C and D) Percent changes in expression of total and phosphomTOR in both groups before and after training. Only MS subjects demonstrated statistically significant
changes in total and phospho-mTOR.

DISCUSSION
In the present study, 8 weeks of resistance training improved several metabolic and
physiological parameters in healthy, previously sedentary subjects as well as previously
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sedentary subjects with the metabolic syndrome. Training had a positive impact on body
composition in both groups (n=19). While body mass did not change, both groups increased
LBM (p≤0.001) and decreased waist circumference (p≤0.05). Additionally, percent body fat
tended to decrease in both groups; however, the decrease was only statistically significant in MS
subjects. The sum of the thickness of 7 skinfolds also tended to decrease in both groups, further
strengthening the evidence that training positively affected body composition.
Several groups have established criteria for diagnosing the metabolic syndrome, and most
include a measurement of visceral adiposity (5). Recent work has demonstrated that obesity may
play a key role in the development of insulin resistance. Adipose tissue acts as an endocrine
tissue, excreting several cytokines that may be involved in the development of insulin resistance.
Tumor necrosis factor-alpha (TNF-α) is a cytokine produced primarily in macrophages which
has been shown to be elevated in obese rodent and human models of obesity. In rodents, overexpression of TNF-α has been shown to induce peripheral insulin resistance, which is restored
with neutralization of TNF-α (126). In humans, it has been demonstrated that obese subjects
express significantly more TNF-α mRNA in fat tissue than in lean controls, and a strong positive
correlation exists between TNF-α mRNA expression and hyperinsulinemia (127-129).
Furthermore, TNF-α mRNA expression and insulin insensitivity decreased with a corresponding
reduction in body mass (127). TNF-α may inhibit tyrosine phosphorylation of the ß-subunit of
insulin receptors and insulin receptor substrate-1 (IRS-1) by insulin, which inhibits insulin
signaling (132).
Adipose tissue also secretes interleukin-6 (IL-6), another cytokine associated with
inflammation. Similar to TNF-α, high plasma concentrations of IL-6 correspond to increased
obesity and insulin resistance (128;133;134). Kern et al. (128) demonstrated that IL-6 may affect
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insulin sensitivity in mouse hepatocytes and human HepG2 cells via mechanisms similar to
TNF-α. Specifically, IL-6 may inhibit insulin receptor activity due to decreased tyrosine
phosphorylation of IRS-1 that inhibits insulin-dependent activation of Akt. However, a study in
IL-6-deficient (IL-6-/-) mice indicates that hypothalamic IL-6 may exert anti-obesity effects
(135). IL-6-/- mice developed type 2 diabetes that was partially ameliorated by IL-6 treatment.
Furthermore, substrate metabolism was impaired in IL-6-/- mice. Similarly, studies in human
skeletal muscle indicate that IL-6 exposure improves glucose metabolism but has no effect on
insulin-dependent glucose uptake (136). It has been demonstrated that contracting skeletal
muscle produces IL-6 that leads to an increase in plasma IL-6 levels (137). Recent evidence
suggests that the effects of IL-6 vary depending on the target tissue. Chronic elevation of
circulating IL-6 levels are an indicator of insulin resistance, while the acute presence of IL-6 may
be beneficial for certain tissues such as skeletal muscle (138).
Other adipocyte secretions include plasminogen activator inhibitor 1 (PAI-1) and
apidonectin. PAI-1 has recently been linked to the development of thrombosis, fibrosis, and
insulin resistance (139). Using PAI-1 deficient mice, Ma and colleagues demonstrated that PAI-1
deficiency protects against diet-induced obesity and insulin resistance, suggesting that PAI-1
may be important in the development of obesity. Others have hypothesized that PAI-1
contributes to a “hypercoagulable” state that may result in increased platelet formation and
associated cardiovascular risks (140).
Adiponectin is a protein secreted by adipocytes. Circulating levels of adiponectin are
inversely related to obesity and insulin resistance, while up-regulation of adiponectin protects
against obesity-induced insulin resistance (141). Adiponectin also acts as an insulin-sensitizing
agent, possibly through phosphorylation and activation of the AMPK signaling pathway (142).
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Excessive adiposity may also adversely affect blood lipids. Indeed, high plasma
triglycerides and reduced HDL cholesterol are typically seen in individuals with abdominal
obesity (120). Moreover, plasma free fatty acid (FFA) concentration is elevated in obese subjects
(121), possibly due to increased fat mass (122). Santomauro and colleagues (125) showed that
treatment with an antilipolytic drug called Acipimox reduced fasting plasma FFA and insulin
concentrations in obese subjects. Furthermore, euglycemic-hyperinsulinemic clamps and glucose
tolerance tests revealed improved glucose tolerance after plasma FFA reduction in obese nondiabetic patients and obese patients with type 2 diabetes.
In this context, we expected that improvements in body composition due to training
would lead to improved insulin sensitivity and other markers of the metabolic syndrome. Both
groups tended to decrease total cholesterol, serum triglycerides, and LDL cholesterol after
training. Despite these improvements, only controls showed a statistically significant
improvement in fasting insulin levels. Fasting insulin and fasting blood glucose tended to
decrease in MS subjects, but the effects were small (d=-0.087 and -0.123, respectively). Fasting
blood glucose was still above 100 mg/dL after training. Glucose infusion rate during the
euglycemic hyperinsulinemic clamp increased 25% in controls (p≤0.05) but was unchanged in
MS subjects.
Skeletal muscle makes up a large percentage of an individual’s body mass and is the
primary site for insulin-stimulated glucose uptake and use (62). It has been widely reported that
muscle contraction increases skeletal muscle glucose uptake (93). Not surprisingly, low physical
activity levels (284;285) and low cardiovascular fitness (286) are associated with an increased
prevalence of the metabolic syndrome. Interestingly, muscular strength may also be associated
with metabolic syndrome prevalence and insulin resistance (287;288). Endurance and resistance
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training have been shown to improve glycemic control (159;164;165) and insulin resistance
(165-167). Many of these benefits can be achieved without any accompanying weight loss.
The lack of improvement in insulin resistance and glycemic control in the present study
may be explained several ways. First, while not statistically significant, the average age of the
controls was approximately 9 years younger than subjects with the metabolic syndrome.
Previous studies have suggested that the quantitative adaptations to resistance exercise are
reduced with age (289;290). In the present study, however, older subjects (both controls and
metabolic syndrome) showed comparable improvements to younger subjects. It is possible that
this observation is due to the extremely sedentary lifestyle of many of the older subjects prior to
participation in the study. It does not appear that this difference in age affected the outcome of
the current study. Second, many studies that suggest resistance training may be effective at
improving insulin resistance demonstrate a decrease in fat mass as a result of training (159;164).
In the present study, fat mass did not change in either group. One possible explanation is that
many of the subjects simply were not strong enough at the beginning of the training program to
cause significant adaptations (figure 1). Volume load is typically higher during periods of high
volume training (weeks 1-4) than during periods of lower volume training (weeks 5-8); however,
volume load was higher during weeks 5-8 for every subject in the present study. Higher volume
work increases general fitness and is associated with greater improvements in body composition
compared to low volume training (291). It is possible that the subjects needed to achieve a
certain threshold of strength before they can lift with enough intensity to force adaptation to the
high volume phase of training.
Normal human skeletal muscle contains a mixture of type I, IIa, and IIx muscle fibers.
Each fiber type is suited for different types of physical activity. Type I (red, slow) fibers contain
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many mitochondria and are well suited for oxidative energy production. While type I fibers can
provide energy for long periods of time, their relatively slow contraction speed and low force
production make them best suited for long-term, low intensity activity (182;184). Conversely,
Type IIx (white, fast) fibers are best suited for energy production via phosphagens and fast
glycolysis. Type IIx fibers have the fastest speed of contraction and highest force production
capabilities, making them well suited for short term, high intensity activity such as resistance
training (35;36). Type IIa fibers are an intermediate fiber type with properties of both type I and
type IIx fibers (184). Training typically causes a shift from type IIx muscle fibers toward type IIa
fibers, indicative of the altered energy need of the trained muscles (182). In view of the divergent
functional capabilities of each skeletal muscle fiber type, it is not surprising that many of the
adaptations to training are at least to some extent fiber type dependent (180) and may occur
through separate cell signaling pathways (199).
Endurance training is associated with improved efficiency of substrate uptake and use by
skeletal muscle. These improvements are brought about by increases in mitochondrial
biogenesis, oxidative enzymes, and fatty acid oxidation (168;169;171;288;292). In addition,
endurance training appears to increase glucose uptake into the cell by increasing the expression
of GLUT4 in skeletal muscle (103). Many of these adaptations are mediated by AMPK and its
downstream targets (293). The adaptations brought about by AMPK activation are similar to the
type I fiber phenotype. Interestingly, type I muscle fiber content (158) and AMPK activation are
positively associated with whole body insulin sensitivity (294).
Resistance training results in increased protein synthesis (177) and may increase GLUT4
expression in skeletal muscle (295;296). The mTOR signaling pathway appears to be crucial in
mediating the adaptations to resistance exercise; however, mTOR’s role in improving insulin
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sensitivity following resistance training has remained elusive. It has been demonstrated in
transgenic mice that knockout of S6-kinase 1 (S6K1), a downstream target of mTOR, results in
decreased pancreatic ß-cell size and a concomitant decrease in glucose-stimulated insulin
secretion (259). Izumiya and colleagues (272) generated a transgenic mouse expressing a
constitutively activated form of Akt1, another protein kinase upstream of mTOR in this
signaling pathway. Activation of Akt1 resulted in type II fiber hypertrophy and reduced fat pad
mass. Additionally, Akt1 activation normalized fasting blood glucose and insulin levels in high
fat/high fructose fed mice. The authors concluded that increased type II muscle mass positively
affected obesity and other metabolic parameters via altered fatty acid oxidation.
Impaired glucose uptake is a major defect in individuals with the metabolic syndrome
(16). Glucose is transported across the plasma membrane via specialized glucose transporter
proteins (GLUTs), of which GLUT4 is the predominant GLUT in human skeletal muscle (75).
Insulin signaling and exercise cause GLUT4 translocation from intracellular pools to the plasma
membrane (87). Increased GLUT4 protein expression after exercise training has been shown to
increase whole body glucose disposal in type 2 diabetics (109). As many as 14 members of the
GLUT family have been identified, including the fructose transporter GLUT5 (75). Stuart and
colleagues (296) demonstrated in a previous study of sedentary, non-metabolic syndrome
subjects that GLUT5 protein expression decreases in skeletal muscle after cycle ergometer
training.
In the present study, resistance training caused a statistically significant increase in the
expression of AMPK, mTOR, ATP synthase, and GLUT4 for the entire group. Disappointingly,
these increases were only weakly correlated with changes in markers for insulin resistance. It has
been demonstrated that AMPK activation may attenuate the mTOR signaling response to
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exercise (297). Moreover, recent work suggests that AMPK signaling may be partially inhibited
by activation of S6K1 through the mTOR signaling pathway (298). The lack of improvement in
insulin responsiveness in the metabolic syndrome subjects in this study may be due to
diminished activation of AMPK and thus decreased mitochondrial biogenesis. While insulin
sensitivity did not improve, resistance training appears to have produced several positive benefits
in both healthy subjects as well as those with the metabolic syndrome. Body composition
improved, along with increases in strength and endurance, which has been shown to improve
functional capabilities and quality of life (299). Additionally, intracellular pathways leading to
increased protein synthesis and mitochondrial biogenesis were activated. Based upon numerous
studies, it appears that long-term activation of these pathways through training will ameliorate
many of the negative aspects of the metabolic syndrome.
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